Abiomed Impella 2.5 and 5.0:
This article was originally published in Clinica
Executive Summary
Abiomed has received Canadian approval for its Impella 2.5 and Impella 5.0 ventricular cardiac assist devices for maintaining circulatory support. The devices are inserted minimally invasively into the left ventricle, where they help pump blood in heart failure patients. The Danvers, Massachusetts company has already CE marked the Impella 2.5 for sale in Europe, and Abiomed has now completed enrolment in a pilot study of the technology in the US. The Impella 5.0, which can also be inserted surgically, is CE-marked too, and is in pilot studies in the US.